These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

586 related items for PubMed ID: 22538032

  • 1. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
    Borhany M, Kumari M, Shamsi T, Naz A, Farzana T.
    J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
    [Abstract] [Full Text] [Related]

  • 2. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
    Ter Avest PC, Fischer K, Gouw SC, Van Dijk K, Mauser-Bunschoten EP.
    Haemophilia; 2010 May; 16(102):71-9. PubMed ID: 20536988
    [Abstract] [Full Text] [Related]

  • 3. FVIII and FIX inhibitors in people living with hemophilia in Cameroon, Africa: a preliminary study.
    Balôgôg PN, Tagny CT, Ndoumba A, Mbanya D.
    Int J Lab Hematol; 2014 Oct; 36(5):566-70. PubMed ID: 25356499
    [Abstract] [Full Text] [Related]

  • 4. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A, Monzini M, Tagariello G, Scaraggi FA, Mannucci PM, Emoclot15 Study Members.
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [Abstract] [Full Text] [Related]

  • 5. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H, Beltrán-Miranda CP, Esparza-Flores MA, Soto-Padilla J, Bergés-García A, Rodríguez-Zepeda MD, Pompa-Garza MT, Jaloma-Cruz AR.
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [Abstract] [Full Text] [Related]

  • 6. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
    Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM, RITS-FITNHES Study Group.
    Haemophilia; 2007 Jul; 13(4):373-9. PubMed ID: 17610550
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The long-term course of factor VIII inhibitors in patients with congenital haemophilia A without immune tolerance induction.
    Caram C, de Souza RG, de Sousa JC, Araújo Pereira T, do Amaral Cerqueira AM, van der Bom JG, Rezende SM.
    Thromb Haemost; 2011 Jan; 105(1):59-65. PubMed ID: 21057702
    [Abstract] [Full Text] [Related]

  • 9. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres.
    Nakar C, Manco-Johnson MJ, Lail A, Donfield S, Maahs J, Chong Y, Blades T, Shapiro A.
    Haemophilia; 2015 May; 21(3):365-373. PubMed ID: 25581638
    [Abstract] [Full Text] [Related]

  • 10. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL, Singleton E, Brady B, White B, Nolan B, Gilmore RM, Ryan C, Keohane C, Jenkins PV, O'Donnell JS.
    Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
    [Abstract] [Full Text] [Related]

  • 11. Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non-interventional study.
    Rivard GE, Rothschild C, Toll T, Achilles K.
    Haemophilia; 2013 May; 19(3):449-55. PubMed ID: 23510123
    [Abstract] [Full Text] [Related]

  • 12. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
    Gouw SC, Van Der Bom JG, Van Den Berg HM, Zewald RA, Ploos Van Amstel JK, Mauser-Bunschoten EP.
    Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
    [Abstract] [Full Text] [Related]

  • 13. [Factor VIII inhibitors in patients suffering from severe haemophilia A: problems of "very low" responders].
    Lutze G, Aumann V, Lutze G, Mittler U.
    Klin Padiatr; 2001 Mar; 213(6):321-4. PubMed ID: 11713709
    [Abstract] [Full Text] [Related]

  • 14. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
    Singleton E, Smith J, Kavanagh M, Nolan B, White B.
    Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
    [Abstract] [Full Text] [Related]

  • 15. Risk of inhibitor development in mild haemophilia A increases with age.
    Mauser-Bunschoten EP, Den Uijl IE, Schutgens RE, Roosendaal G, Fischer K.
    Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
    [Abstract] [Full Text] [Related]

  • 16. Rituximab for the treatment of patients with very high-titre acquired factor VIII inhibitors refractory to conventional chemotherapy.
    Field JJ, Fenske TS, Blinder MA.
    Haemophilia; 2007 Jan; 13(1):46-50. PubMed ID: 17212724
    [Abstract] [Full Text] [Related]

  • 17. Treatment of haemophilia A in Tunisia: efficacy and inhibitor study.
    Houissa B, Mliki ML, Abdelkafi S, Bouslama M, Zaïer M, Mahjoub T, Kortas M, Ghachem L, Yacoub S.
    Hamostaseologie; 2003 Aug; 23(3):144-8. PubMed ID: 12923586
    [Abstract] [Full Text] [Related]

  • 18. Development of inhibitors in haemophilia. Ongoing epidemiological study.
    Serban M, Mihailov D, Pop L, Ionita H, Ursu E, Talpos-Niculescu S, Ritli L, Baghiu D, Uscatescu V, Petrovanu C, Stancu P, Savescu D, Cucuianu A, Schramm W.
    Hamostaseologie; 2011 Nov; 31 Suppl 1():S20-3. PubMed ID: 22057218
    [Abstract] [Full Text] [Related]

  • 19. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
    Unuvar A, Kavakli K, Baytan B, Kazanci E, Sayli T, Oren H, Celkan T, Gursel T.
    Haemophilia; 2008 Mar; 14(2):315-22. PubMed ID: 18081830
    [Abstract] [Full Text] [Related]

  • 20. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanská E, Campos M, Benedik-Dolničar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Šalek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O, ObsITI study group, ObsITI committee.
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.